Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Frederic Colombel

Showing results (351-360 of 377) with videos related to

Pageof 38
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 10, 2019
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative ColitisDavid M Faleck, Adam Winters, Shreya Chablaney, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2018
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel DiseasesJoseph Meserve, Satimai Aniwan, Jenna L Koliani-Pace, et al.
Science Translational Medicine|October 5, 2018
Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individualsMathieu Uzzan, Minami Tokuyama, Adam K Rosenstein, et al.
Gut|September 15, 2022
Biopsy and blood-based molecular biomarker of inflammation in IBDCarmen Argmann, Ruixue Hou, Ryan C Ungaro, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative ColitisDana Lukin, David Faleck, Ronghui Xu, et al.
Inflammatory Bowel Diseases|May 4, 2019
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease OutcomesJenna L Koliani-Pace, Siddharth Singh, Michelle Luo, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2023
Myeloid cell influx into the colonic epithelium is associated with disease severity and non-response to anti-Tumor Necrosis Factor Therapy in patients with Ulcerative ColitisDivya Jha, Zainab Al-Taie, Azra Krek, et al.
Gut|November 1, 2016
Development of an index to define overall disease severity in IBDCorey A Siegel, Cynthia B Whitman, Brennan M R Spiegel, et al.
The American Journal of Gastroenterology|November 4, 2018
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
The American Journal of Gastroenterology|June 28, 2018
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
Pageof 38

Showing results (351-360 of 377) with videos related to

Sort By:
Pageof 38
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 10, 2019
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative ColitisDavid M Faleck, Adam Winters, Shreya Chablaney, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2018
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel DiseasesJoseph Meserve, Satimai Aniwan, Jenna L Koliani-Pace, et al.
Science Translational Medicine|October 5, 2018
Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individualsMathieu Uzzan, Minami Tokuyama, Adam K Rosenstein, et al.
Gut|September 15, 2022
Biopsy and blood-based molecular biomarker of inflammation in IBDCarmen Argmann, Ruixue Hou, Ryan C Ungaro, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative ColitisDana Lukin, David Faleck, Ronghui Xu, et al.
Inflammatory Bowel Diseases|May 4, 2019
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease OutcomesJenna L Koliani-Pace, Siddharth Singh, Michelle Luo, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2023
Myeloid cell influx into the colonic epithelium is associated with disease severity and non-response to anti-Tumor Necrosis Factor Therapy in patients with Ulcerative ColitisDivya Jha, Zainab Al-Taie, Azra Krek, et al.
Gut|November 1, 2016
Development of an index to define overall disease severity in IBDCorey A Siegel, Cynthia B Whitman, Brennan M R Spiegel, et al.
The American Journal of Gastroenterology|November 4, 2018
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
The American Journal of Gastroenterology|June 28, 2018
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
Pageof 38